ir.heatbio.com/press-releases/detail/637/...-2019-results-and
|
neue Shares Dilution
As of May 10, 2019, there were 34,065,652 shares of Common Stock, $0.0002 par value per share, outstanding.
As of August 12, 2019, there were 34,066,652 shares of Common Stock, $0.0002 par value per share, outstanding.
Aus dem Q4 2018 und Q2 2019
As of June 30, 2019, the Company has outstanding warrants to purchase 9,030,730 shares of common stock issuable at a weighted-average exercise price of $1.89 per share.
The Company has a total of 9,030,730 warrants outstanding at a weighted average exercise price of $1.89 to purchase its common stock as of December 31, 2018. These warrants are summarized as follows:
Issuance Date | Number of Shares | Exercise Price | Expiration Date | |||
3/10/2011 | 1,738 | $ 4.80 | 3/10/2021 | |||
3/23/2016 | 296,159 | $ 10.00 | 3/23/2021 | |||
5/7/2018 | 4,132,833 | $ 1.58 | 5/8/2023 | |||
11/26/2018 | 4,600,000 | $ 1.65 | 11/26/2023 |
|
Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
8 | 4.379 | Heat Biologics - 3 Krebsmittel in der Pipeline! | Balu4u | Highländer49 | 08.03.24 13:53 | |
2 | Face the Heat | VEB Plaste und Ela. | Advamillionär | 24.04.21 23:58 |